Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity of nOPV2, bOPV and IPV Schedules
NCT06114810Phase 4Unknown
- Sponsor
- icddr,b
- Start
- Nov 2023
- Primary completion
- Jun 2024
- Modality
- Live Biotherapeutic Products, Vaccines & Immunotherapeutics
01
Overview
Phase 4, randomised, open-label trial of nOPV2 in poliomyelitis (4 arms), sponsored by icddr,b. Primary endpoint: Cumulative seroconversion to all serotypes at 18 weeks. Status: unknown.
02
Drugs
nOPV2
03
Conditions
poliomyelitis
Beyond the preview
Go deeper on NCT06114810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06114810.